



1-BENZYL-3-THIOARYL-2-CARBOXYINDOLES AS POTENT NON-PEPTIDE ENDOTHELIN ANTAGONISTS

Amy M. Bunker*, Jeremy J. Edmunds, Kent A. Berryman, Donnelle M. Walker, Michael A. Flynn, Kathy M. Welch, and Annette M. Doherty

Departments of Chemistry and Cardiovascular Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105


Abstract: Endothelin-1 is a potent vasoconstrictor which is thought to be involved in many human disease states. We have developed a series of indole non-peptide endothelin antagonists which display nanomolar receptor affinity. The representative compound from this series is PD 159433 (**22**), an ET_A selective antagonist with an IC₅₀ of 2 nM. The discovery, synthesis and structure-activity relationships of this series of compounds are described. Copyright © 1996 Elsevier Science Ltd

Introduction: The family of endothelin peptides consist of endothelin-1 (ET-1), endothelin-2 (ET-2), endothelin-3 (ET-3), and the vasoactive intestinal contractor (VIC). Endothelin-1, a 21 amino acid bicyclic peptide isolated from cultured porcine endothelial cells, was the first of this series to be identified.^{1,2} Since this discovery, endothelin-2 and endothelin-3, which differ by 2 and 6 amino acids respectively, have been reported and characterized.^{3,4} The biological effects of the endothelins has been shown to occur through the interaction of the peptides with specific receptor subtypes. The ET_A receptor subtype, which is selective for ET-1, is predominantly found in the vascular smooth muscle. The ET_B receptor subtype is non-selective, binding ET-1, ET-2, and ET-3 with similar affinity, and has been found in a variety of tissues including human cultured umbilical vein and human mammary arteries and veins.^{5,6,7,8}

The vasoactive and mitogenic actions of endothelin has implicated this peptide in the pathogenesis of a number of disease states including renal failure, pulmonary hypertension, cerebral ischemia and vasospasm, endotoxic shock, and congestive heart failure.⁹ The ET_A receptor is known to mediate a major portion of the vasoconstrictor activity of endothelin in human vessels.^{10,11}


There have been a number of peptide and non-peptide endothelin antagonists reported in the literature.¹²⁻²⁰ These include a related series of 1,3-diaryl-2-carboxyindoles previously disclosed from these laboratories²¹ and others.²²

Results and Discussion: Screening of the Parke-Davis compound library afforded several moderately active compounds when tested in rabbit renal artery vascular smooth muscle cells expressing the ET_A receptors.^{14,23} We selected the lead structure, compound **1**, for synthetic modification and soon discovered that compound **2** showed moderate activity, confirming that an acidic substituent at C-2 and a lipophilic substituent at C-3 were essential for receptor binding activity. Compound **3**, being 4-fold less potent than the benzothiophene, **2**, demonstrated that the 1 position played some role in receptor binding activity.




1

ET_A IC₅₀ 6μM
hET_A IC₅₀ 8.8μM
hET_B IC₅₀ >100μM



2

ET_A IC₅₀ 5.9μM
hET_B IC₅₀ >25μM




3

ET_A IC₅₀ 23μM
hET_B IC₅₀ >25μM

Therefore, following the disclosure of a series of indanes^{17,22} as endothelin antagonists we directed our attention to a series of N1-substituted indoles. Since previous SAR studies revealed that, in general, electron donating substituents on the aromatic rings favored ET_A binding affinity,¹⁴ we decided to synthesize 1-benzyl-3-thioaryl-indoles that incorporated these substituents.

Structure-Activity Relationships:

Table 1 - 1-benzyl-3-thioaryl-2-carboxyindoles



Ex	R1	R2	R3	R4	R5	R6	R7	R8	hET _A I C ₅₀ (μM)	hET _B C ₅₀ (μM)	AAR-A (μM)	AAR-B (μM)	ET _A (pA ₂)	ET _B (pA ₂)
4	OMe	H	H	H	H	H	H	H	4.6	15	-	-	-	-
5	OMe	H	H	H	H	H	OMe	OMe	0.16	0.87	-	-	-	-
6	OMe	H	H	H	-(OCH ₂ O)-	H	H	H	0.086	7.4	-	-	-	-
7	OMe	H	H	H	-(OCH ₂ O)-	OMe	OMe	OMe	0.02	1.1	0.033	0.21	7.0	-
8	OMe	H	H	H	-(OCH ₂ O)-	H	OPr	H	0.59	6.7	-	-	-	-
9	OMe	H	H	H	-(OCH ₂ O)-	OBn	OMe	OMe	0.081	0.69	-	-	-	-
10	OMe	H	H	H	-(OCH ₂ O)-	OMe	OBn	OMe	2.0	1.6	-	-	-	-
11	OMe	H	H	H	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OMe	0.084	0.76	-	-	-	-
12	OMe	H	H	OMe	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OMe	0.38	2.9	-	-	-	-
13	OMe	H	H	OMe	-(OCH ₂ O)-	OMe	OMe	OMe	0.058	1.1	-	-	-	-
14	OMe	OMe	H	OMe	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OMe	0.17	0.42	-	-	-	-
15	OMe	OMe	H	H	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OMe	0.041	0.17	0.065	0.17	6.3	6.2
16	-(OCH ₂ O)-	H	H	H	-(OCH ₂ O)-	H	H	H	0.38	4.5	-	-	-	-
17	-(OCH ₂ O)-	H	H	H	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OBn	0.1	0.42	-	-	-	-
18	-(OCH ₂ O)-	H	H	H	-(OCH ₂ O)-	OMe	OBn	OMe	0.62	0.49	3.4	0.74	-	-
19	-(OCH ₂ O)-	H	H	H	-(OCH ₂ O)-	OMe	OMe	OMe	0.005	0.28	0.1	1.1	7.3	6.2
20	OMe	OMe	OMe	H	-(OCH ₂ O)-	-(OCH ₂ O)-	OMe	OBn	0.007	0.23	0.064	0.17	6.9	-
21	OMe	OMe	OMe	H	-(OCH ₂ O)-	OMe	OBn	OMe	>2.5	>2.5	-	-	-	-
22	OMe	OMe	OMe	H	-(OCH ₂ O)-	OMe	OMe	OMe	0.002	0.38	0.0046	0.44	7.5	5.5

From Table 1 it is evident that at positions R₄, R₅, and R₆ activity was enhanced from the unsubstituted compounds **4** and **5**, by the addition of a methylenedioxy group, as seen in compounds **6** and **7**. Since the methylenedioxy moiety was an improvement over the unsubstituted compounds, the substitution on this ring was kept constant.


Substitution at the R₄ position with electron donating groups, such as a methoxy group, did not appear to enhance binding activity, as seen by comparing compounds **12-14** with their unsubstituted analogs compound **11**, **7**, and **15** respectively.

The addition of multiple electron donating groups at R₇ and R₈ improved activity significantly, as seen by comparing compounds **4** and **5**, compounds **6** and **7**, and compounds **16** and **19**. Further SAR involving compounds **7-11**, **12-13**, **16-19**, and **20-22** clearly demonstrated the need for methoxy substituents at R₇ and R₈.

Positions R₁, R₂, and R₃ were also substituted with a variety of electron donating groups. We synthesized several potent compounds incorporating the methylenedioxy moiety and methoxy substituents, exemplified by compounds **11**, **15**, **17**, and **20**. Substitution at each of the R₁, R₂, and R₃ positions with a methoxy group led to the discovery of PD 159433 (**22**), an ET_A selective endothelin antagonist. This compound potently inhibited the release of arachidonic acid from rabbit renal vascular smooth muscle cells stimulated by ET-1, and demonstrated functional antagonism of ET-1 stimulated vasoconstriction in isolated strips of rabbit femoral arteries.

Synthesis: Treatment of sodium salts of 2-carboxyindoles²¹ with diaryldisulfides²⁴ and diazomethane work-up led to good yields of the 2-methoxycarbonyl-3-thioaryl-indoles. Benzylation of the indoles proceeded readily by treatment with the appropriate benzyl chlorides with hydrolysis affording the required target compounds, as seen in Scheme 1.

Scheme 1: 1-benzyl-3-thioaryl-2-carboxyindoles



(a) i 3.0 equiv NaH, 1.0 equiv diaryldisulfide, DMF, 60 °C; ii 3.0 equiv TMSCHN₂, toluene:MeOH 4:1, 71% yield (b) i 1.25 equiv NaH, DMF, 1.1 equiv (3,4-methylenedioxy)benzyl chloride, 0 °C, 64% yield; ii 15.0 equiv LiOH, THF:MeOH:H₂O 5:1:1, 64% yield.

Biological Evaluation: Structure-activity relationships were investigated using IC₅₀ values obtained from receptor binding in Ltk- cells expressing recombinant human receptors (hET_A), and CHO-K1 cells expressing recombinant human receptors (hET_B).^{14,25} Selected compounds were evaluated for antagonist activity by measuring the ability of these compounds to reduce ET-1 stimulated arachidonic acid release (AAR) in cultured rabbit renal vascular smooth muscle cells.^{14,26} In addition, in vitro antagonism of ET-1 stimulated vasoconstriction was carried out in rabbit femoral artery, ET_A(pA₂), to demonstrate a functional response to antagonism of ET_A in this isolated tissue. Inhibition of sarafotoxin-6c stimulated vasoconstriction was carried out in rabbit pulmonary artery, ET_B(pA₂).^{25,27}

Conclusions: Extensive investigation of electron donating substituents on all three aromatic rings led to the discovery of ET_A selective indoles, such as compounds **19**, **20**, and **22**. The ability of compound **22**, for example, to inhibit the release of arachidonic acid (AAR), and to inhibit the contraction of rabbit femoral artery, upon stimulation with ET-1 demonstrated that these compounds are functional antagonists of the ET_A receptor. These compounds should prove useful in elucidating the physiological and pathophysiological role of endothelin.

References:

1. Hickey, K. A.; Rubanyani, G.; Paul, R. J.; Highsmith, R. F. *Am. J. Physiol.* **1985**, *248*, C550.
2. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A. *Nature* **1988**, *332*, 411.
3. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 2863.
4. Shinmi, O.; Kimura, S.; Sawamura, T.; Sugita, Y.; Yoshizawa, T.; Uchiyama, Y.; Yanagisawa, M.; Goto, K.; Masaki, T.; Kanazawa, I. *Biochem. Biophys. Res. Commun.* **1989**, *164*, 587.

5. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanashi, S. *Nature* **1990**, *348*, 730.
6. Sakuri, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. *Nature* **1990**, *348*, 732.
7. Davenport, A. P.; O'Reilly, G.; Molenaar, P.; Maguire, J. J.; Kuc, R. E.; Sharkey, A.; Bacon, C. R.; Ferro, A. *J. Cardiovasc. Pharmacol.* **1993**, *22*, S22.
8. Seo, B.; Oemar, B. S.; Siebenmann, R.; Von Segesser, L.; Luscher, T. F. *Circulation* **1994**, *89*, 1203.
9. Doherty, A. M. *J. Med. Chem.* **1991**, *35*, 1493.
10. Maguire, Janet J.; Kuc, Rhonda E.; O'Reilly, Gillian; Davenport, Anthony P. *Br. J. Pharmacol.* **1994**, *113*, 49.
11. Davenport, Anthony P.; O'Reilly, Gillian; Kuc, Rhonda E. *Br. J. Pharmacol.* **1995**, *114*, 1110.
12. Ishikawa, K.; Fukami, T.; Nagase, T.; Fujita, K.; Hayama, T.; Niyama, K.; Mase, T.; Ihara, M.; Yano, M. *J. Med. Chem.* **1992**, *35*, 2139.
13. Ihara, M.; Noguchi, K.; Saeki, T.; Fukuroda, T.; Tsuchida, S.; Kimura, S.; Fukami, T.; Ishikawa, K.; Nishikibe, M.; Yano, M. *Life Sci.* **1991**, *50*, 247.
14. Doherty, A. M.; Patt, W. C.; Edmunds, J. J.; Berryman, K. A.; Reisdorph, B. R.; Plummer, M. S.; Shahripour, A.; Lee, C.; Cheng, X.; Walker, D. M.; Haleen, S. J.; Keiser, J. A.; Flynn, M. A.; Welch, K. M.; Hallak, H.; Taylor, D. G.; Reynolds, E. E. *J. Med. Chem.* **1995**, *38*, 1259.
15. Cody, W. L.; Doherty, A. M.; He, J. X.; Depue, P. M.; Rapundalo, S. T.; Hingorani, G. A.; Major, T. C.; Panek, R. L.; Haleen, S.; LaDouceur, D.; Reynolds, E. E.; Hill, K. E.; Flynn, M. A. *J. Med. Chem.* **1992**, *35*, 3301.
16. Cody, W. L.; Doherty, A. M.; He, J. X.; Depue, P. M.; Wait, L. A.; Toppliss, J. G.; Haleen, S. J.; LaDouceur, D.; Reynolds, E. E.; Hill, K. E.; Flynn, M. A. *Med. Chem. Res.* **1993**, *3*, 154.
17. Elliott, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Leber, J. D.; Erhard, K. F.; Nambi, P.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Bean, J. W.; DeBrosse, C. W.; Eggleston, D. S.; Brooks, D. P.; Feuerstein, G.; Ruffolo, R. R.; Weinstock, J.; Gleason, J. G.; Peishoff, C. E.; Ohlstein, E. H. *J. Med. Chem.* **1994**, *37*, 1553.
18. Walsh, T. F.; Fitch, K. J.; Chakravarty, K.; Williams, D. L.; Murphy, K. A.; Nolan, N. A.; O'Brien, J. A.; Lis, E. V.; Pettibone, D. J.; Kivlighn, S. D.; Gabel, R. A.; Zingaro, G. J.; Krause, S. M.; Siegl, P. K. S.; Clineschmidt, B. V.; Greenlee, W. J. ACS National Meeting: Washington D. C., August 1994, MEDI 145.
19. Roux, S. P.; Clozel, M.; Sprecher, U.; Gray, G.; Clozel, J. P. *Circulation* **1993**, *88*, I-170.
20. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; Nishikibe, J.; Yano, M. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 4892.
21. Bunker, A. M.; Edmunds, J. J.; Berryman, K. A.; Reynolds, E. E.; Walker, D. M.; Flynn, M. A.; Welch, K. M.; Doherty, A. M. *Bioorg. Med. Chem. Lett.*, accepted **1996**.
22. Cousins, R. D.; Elliot, J. D.; Lago, M. A.; Leber, J. D.; Peishoff, C. E. Endothelin Receptor Antagonists, Smith-Kline Beecham Corporation, **WO 93/08799**
23. Connor, D. T.; Cetenko, W. A.; Mullican, D.; Sorenson, R. J.; Unangst, P. C.; Weikert, R. J.; Aldolphson, R. L.; John, A.; Thueson, D. O.; Wright, C. D.; Conroy, M. C. *J. Med. Chem.* **1992**, *35*, 958.
24. Berryman, K. A.; Bunker, A. M.; Doherty, A. M.; Edmunds, J. J. Warner-Lambert Company, **US 5,482,960**
25. Reynolds, E. E.; Keiser, J. A.; Haleen, S. J.; Walker, D. M.; Davis, L. S.; Olszewski, B.; Taylor, D. G.; Hwang, O.; Welch, K. M.; Flynn, M. A.; Thompson, D. M.; Edmunds, J. J.; Berryman, K. A.; Lee, C.; Reisdorph, B. R.; Cheng, X. M.; Patt, W. C.; Doherty, A. M. *J. Pharmacol. Exp. Ther.* **1995**, *273*, 1410.
26. Reynolds, E. E.; Mok, L.; Kurokawa, S. *Biochem. Biophys. Res. Commun.* **1989**, *160*, 868.
27. Cody, W. L.; Doherty, A. M.; He, J. X.; Depue, P. L.; Waite, L. A.; Toppliss, J. G.; Haleen, S. J.; LaDouceur, D.; Flynn, M. A.; Hill, K. E.; Reynolds, E. E. *Med. Chem. Res.* **1993**, *3*, 154.

(Received in USA 15 April 1996; accepted 14 May 1996)